文献速递淋巴瘤

Camidanlumab tesirine治疗复发或难治性经典型霍奇金淋巴瘤:一项2期研究

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
PubMed 文献 · Blood Adv · 2025-01-01

该2期研究评估了抗CD25抗体药物偶联物camidanlumab tesirine(Cami)在经brentuximab vedotin和PD-1抑制剂治疗后复发/难治性经典型霍奇金淋巴瘤(cHL)患者中的疗效与安全性。117例患者接受45 μg/kg(第1-2周期)后30 μg/kg(每3周,≤1年)静脉给药,总缓解率(ORR)为70.1%(95%CI 60.9-78.2),完全缓解率(CRR)为33.3%(95%CI 24.9-42.6),中位无进展生存期(PFS)为9.13个月(95%CI 5.3-15.0),中位总生存期(OS)未达到。Cami在该经重度治疗人群中有效,但安全性问题突出。

要点

  • ORR达70.1%,CRR为33.3%,中位PFS为9.13个月。
  • 28.2%患者因治疗中出现的不良事件停药。
  • 8例(6.8%)发生吉兰-巴雷型或多神经根病型事件。

核心结论

  • Cami在经重度治疗的复发/难治性cHL患者中有效,但疗效被突出的安全性问题所掩盖。

研究设计与样本

  • 2期ADCT-301-201研究,纳入117例既往接受≥3线系统治疗(或不适合造血干细胞移植者≥2线)的复发/难治性cHL成人患者。
  • 患者接受Cami 45 μg/kg静脉给药(第1-2周期每3周一次),随后30 μg/kg静脉给药每3周一次,最多1年。
  • 主要终点为按2014 Lugano分类的总缓解率(ORR),次要终点包括完全缓解率(CRR)、无进展生存期(PFS)和总生存期(OS)。

主要发现

  • 中位年龄37.0岁(范围19-87)。
  • ORR为70.1%(95%CI 60.9-78.2),CRR为33.3%(95%CI 24.9-42.6)。
  • 中位PFS为9.13个月(95%CI 5.3-15.0),中位OS未达到。
  • 33例(28.2%)因治疗中出现的不良事件停药,最常见原因为皮肤和皮下组织疾病(10例[8.5%])、感染和侵染(5例[4.3%])及神经系统疾病(5例[4.3%])。
  • 8例(6.8%)发生吉兰-巴雷型或多神经根病型事件。

关键数值与推荐

  • 总缓解率(ORR)为70.1%(95%CI 60.9-78.2)。
  • 完全缓解率(CRR)为33.3%(95%CI 24.9-42.6)。
  • 中位无进展生存期(PFS)为9.13个月(95%CI 5.3-15.0)。
  • 中位总生存期(OS)未达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL after brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 previous lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 μg/kg IV once every 3 weeks for ≤1 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barré-type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Herrera AF, Ansell SM, Zinzani PL, et al. Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study. Blood Adv. 2025. PMID: 40811783. doi:10.1182/bloodadvances.2024015600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。